Navigation Links
Viral Genetics Issues 2010 Year in Review, 2011 Outlook
Date:2/2/2011

SAN MARINO, Calif., Feb. 2, 2011 /PRNewswire/ -- Viral Genetics (Pink Sheets: VRAL) ("the Company") has released its 2010 Year in Review and 2011 Outlook by CEO Haig Keledjian, available on the Company website (www.viralgenetics.com). In 2010 the Company moved closer to its goal of bringing new drugs to market by positioning itself for the significant step of advancing the clinical trial process in 2011. The Company expanded its research facilities and capabilities and is looking forward to gathering data from potential drug therapies using its patented Metabolic Disruption Technology (MDT) and Targeted Peptide Technology (TPT). New data sources include an investigator study of MDT therapies for drug-resistant cancers at Scott and White Hospital this spring, funded in part by a recent $1.5 million anonymous grant to the hospital.

"Progress throughout the past year has brought us closer to fulfilling our mission of bringing new drug therapies to the marketplace," notes Viral Genetics CEO Haig Keledjian in the review. "In 2010 we made concrete, measurable steps towards that goal, while also expanding our research to include the development of biofuel technologies through our new subsidiary, VG Energy. We're well positioned to execute against our business objectives in 2011."

Viral Genetics' patents and proprietary technology are being developed in collaboration with several Texas A&M University researchers and support from the State of Texas. Last year, the Company's lead scientist, Dr. M. Karen Newell Rogers, joined the faculty at Texas A&M University Health Science Center's College of Medicine and the Department of Surgery, Scott and White Hospital in Temple, Texas. Now located in a hospital environment and surrounded by leading clinicians, Dr. Newell Rogers has access to significantly enhanced resources for transiti
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
10. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
11. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Minolta, Inc. (Konica Minolta) ( Tokyo : ... Ltda., an X-ray system equipment manufacturer based in Minas ... healthcare sales company, Konica Minolta Healthcare do ... market investment and growth With ... healthcare technical advancements and efficiencies are required. Aging and ...
(Date:7/2/2015)... julio de 2015 BGI anunció hoy que ... alto rendimiento en Hong Kong ... (CAP). La instalación de BGI en Hong Kong ... próxima generación que recibe la certificación CAP en ... en prácticas de laboratorio clínico. Junto con el exitoso ...
(Date:7/2/2015)... CHICAGO, Ill. , July 2, 2015  AbbVie ... financial results on Friday, July 24, 2015, before the ... webcast of the earnings conference call at 8 a.m. ... through AbbVie,s Investor Relations website at www.abbvieinvestor.com . ... after 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3BGI recibe la acreditación del College of American Pathologists (CAP) 2
... Dec. 10 The US Food and,Drug Administration ... small,open, long-term, clinical studies in patients with gastro-esophageal ... study) or NEXIUM(R) (LOTUS study) treatment., AstraZeneca ... conclusion which states,"FDA continues to conclude that long-term ...
... 3 Results Released at American Society of Hematology ... Genta,Incorporated (Nasdaq: GNTA ) announced the release ... patients in the Company,s randomized Phase,3 trial of ... lymphocytic leukemia (CLL). The new data show that,patients ...
Cached Medicine Technology:FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 2FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 3FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 4Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 2Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 3Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 4Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 5Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 6
(Date:7/2/2015)... ... 02, 2015 , ... Healthpointe is pleased to ... spine surgery team at their Anaheim clinic. Dr. Krishnareddy will be treating patients ... spine and spine surgery, Dr. Krishnareddy also specializes in the wrist, hip, shoulder, ...
(Date:7/2/2015)... CORNER, VA (PRWEB) , ... July 02, 2015 ... ... innovative technology solutions and management consulting services to the federal government, has announced ... five-year, Indefinite-Delivery, Indefinite-Quantity (IDIQ), Business Management Office Support Services (BMOSS) contract not to ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. ... has been retained to lead a national chief executive officer recruitment ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
(Date:7/2/2015)... ... 2015 , ... AvePoint Public Sector, Inc., a wholly owned subsidiary ... today announced it was named the recipient of the 2015 GTRA ConVurge Tech Award ... by the Government Technology Research Alliance (GTRA), was presented June 29 during the ConVurge ...
(Date:7/2/2015)... ... July 02, 2015 , ... Today, East Liverpool City Hospital announced Pam ... East Liverpool City Hospital (ELCH). Pam is currently the Chief Nursing Officer at ELCH ... surgery. Pam holds a master’s degree in health care administration as well as nursing. ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3
... highly effective in preventing the behavioral and academic problems ... a five-year study led by researchers at Lehigh Universitys ... and funded by the National Institute of Mental Health ... children aged 3 to 5 who have shown significant ...
... Diabetes patients could benefit from new research at the ... the intestine that can taste the sugar content of ... receptor that senses sugar and artificial sweeteners is not ... intestine. The discovery will open new avenues for the ...
... misinformation onlineconsequences could be deadly , The Internet ... to spread false ideas about HIV/AIDS, which could have ... paper in PLoS Medicine. , "It may seem remarkable ... is still denial that the virus is the cause ...
... with organ transplants, resigned to a lifetime of anti-rejection ... respite, say researchers at Lucile Packard Children,s Hospital and ... blood sample, the scientists have identified for the first ... small group of patients who beat the odds and ...
... were more likely to be uninsured or covered by ... report in the August issue of Archives of Otolaryngology-Head ... Laryngeal [voice box] cancer is diagnosed in nearly 10,000 ... is among the most common cancers in the upper ...
... STANFORD, Calif. - As U.S. policy experts continue to ... a new study from the Stanford University School of ... group of patients reduce their overall risk of heart ... a cost-effective way. , Case management makes use of ...
Cached Medicine News:Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 2Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 3Health News:Discovery of 'sugar sensor' in intestine could benefit diabetes 2Health News:HIV denialists spread misinformation online -- consequences could be deadly; and more 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 3Health News:Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 3
... Narkotron II is a comprehensive vital sign monitor. , ... quality, affordable products for efficiency in patient care., ... 2 - Temp - Multi-gas Sensor (HAL, ... )., ,Optional Functions: ,5-Lead ECG - FiO 2 ...
... monitor is a low-cost, multi-parameter monitor designed ... and surgery. The large display provides bright ... from across the room. The intuitive design ... the monitor in just minutes., ,Standard ...
... the features needed for quality, comprehensive portable ... color display allows you to see up ... ECG. The touch screen allows easy navigation ... gloves or temperature., ,Standard features include ...
... Compact all-in-one anesthesia monitor., ... monitor designed for use in the ... room and PACU. The Cardiocap/5 offers ... the monitoring of oxygenation and circulation ...
Medicine Products: